← All trials
NCT06041061
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 13, 2023
- Primary completion
- Mar 31, 2024
- Completion date
- Aug 31, 2028
- First posted
- Sep 18, 2023
- Last posted
- Sep 18, 2023
- Enrollment
- 18000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sinocelltech Ltd.Lead sponsor
- Government of ChinaCollaborator
- Government of ChinaCollaborator
- Government of ChinaCollaborator
- Government of ChinaCollaborator
- Government of ChinaCollaborator
- Government of ChinaOverall official - principal investigator
- Government of ChinaOverall official - principal investigator
- Government of ChinaOverall official - principal investigator
- Government of ChinaOverall official - principal investigator
- Government of ChinaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.